Reaction Details |
| Report a problem with these data |
Target | Cytochrome P450 1A2 |
---|
Ligand | BDBM50138611 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEBML_51352 |
---|
IC50 | >100000±n/a nM |
---|
Citation | Koltun, DO; Marquart, TA; Shenk, KD; Elzein, E; Li, Y; Nguyen, M; Kerwar, S; Zeng, D; Chu, N; Soohoo, D; Hao, J; Maydanik, VY; Lustig, DA; Ng, KJ; Fraser, H; Zablocki, JA New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties. Bioorg Med Chem Lett14:549-52 (2003) [PubMed] |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Cytochrome P450 1A2 |
---|
Name: | Cytochrome P450 1A2 |
Synonyms: | CP1A2_HUMAN | CYP1A2 | CYPIA2 | Cholesterol 25-hydroxylase | Cytochrome P(3)450 | Cytochrome P450 1A | Cytochrome P450 1A2 (CYP1A2) | Cytochrome P450 4 | Cytochrome P450-P3 |
Type: | Enzyme |
Mol. Mass.: | 58423.38 |
Organism: | Homo sapiens (Human) |
Description: | P05177 |
Residue: | 516 |
Sequence: | MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARLRFSIN
|
|
|
BDBM50138611 |
---|
n/a |
---|
Name | BDBM50138611 |
Synonyms: | CHEMBL150614 | N-(9-Ethyl-9H-carbazol-3-yl)-2-{4-[(R)-2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-acetamide |
Type | Small organic molecule |
Emp. Form. | C31H35N5O3S |
Mol. Mass. | 557.706 |
SMILES | CCn1c2ccccc2c2cc(NC(=O)CN3CCN(C[C@@H](O)COc4ccc5sc(C)nc5c4)CC3)ccc12 |
Structure |
|